Macro

Search catalysts, news stories, and pressures, or browse the trust-weighted news feed below.

Home tech energy finance healthcare defense industrial consumer communication utilities real estate raw materials

← back

healthcare · sector mood

1999

year mood +0.15 · -0.12 to +0.30 across 12 mo

Monthly mood

bearish −1 +1 bullish

month values ▾

Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
+0.30	+0.20	+0.20	+0.09	+0.20	+0.20	+0.20	+0.20	-0.12	+0.10	+0.10	+0.10

Money rotated out of 'old economy' pharma into internet stocks, leaving my franchise neglected and flat, while drug-pricing politics began resurfacing ahead of the 2000 election even as genomics excitement built.

How this mood is scored ▾

Each day the model reads that day's news for the sector and asks, as someone who owns assets or makes their living in it: how am I feeling this month, and why? The month's mood is that running answer, tied to the specific events driving it (the story shown above). It leans on trusted, higher-impact reporting, and on the prior month when a month is quiet, so one loud headline can't swing it. The read updates daily through the month; once a month ends, its mood is locked. This year is read live from the news the pipeline actually collected (hover a bar for its story count). · last computed Jul 11, 2026

Top healthcare stories of 1999

Apr

Astra and Zeneca merge to form $37B AstraZeneca pharmaceuticalonline.com →

Astra AB and Zeneca Group PLC completed their $37 billion merger, forming AstraZeneca PLC, with operations in over 100 countries and a strong US presence. The integration process began immediately, supported by a unified brand identity and new corporate logo. As a leading pharmaceutical firm, AstraZeneca focuses on key therapeutic areas including oncology, cardiovascular, and respiratory products, positioning it for significant market influence.

Sep

First gene therapy death stalls field, sparks reforms livescience.com →

Jesse Gelsinger, an 18-year-old with OTC deficiency, died in 1999 from a severe immune reaction to an adenovirus-based gene therapy trial at the University of Pennsylvania. The incident exposed ethical lapses, including undisclosed risks and investigator conflicts of interest, triggering FDA investigations, trial halts, and stricter clinical oversight. The tragedy led to a prolonged stall in gene therapy funding and development, though the field eventually rebounded with advances in vector safety and CRISPR technology.